Author/Authors :
Tian، نويسنده , , Zhijun and Zhou، نويسنده , , Guohui and Zheng، نويسنده , , Bao-Liang and Qiu، نويسنده , , Hua-Ji and Ni، نويسنده , , Jianqiang and Yang، نويسنده , , Huan-Liang and Yin، نويسنده , , Xun-Nan and Hu، نويسنده , , Shou-Ping and Tong، نويسنده , , Guang-Zhi، نويسنده ,
Abstract :
The hemagglutinin (HA) gene of A/Swine/Inner Mogolian/547/2001 (H3N2) swine influenza virus (SIV) was recombined into the genome of pseudorabies virus (PRV) Bartha-K61 vaccine strain, generating a recombinant PRV expressing the HA gene, designated as rPRV-HA. One group of 15 mice was inoculated intranasally (i.n.) with 105.0 PFU of rPRV-HA, and another two control groups of mice (15 mice per group) were mock-inoculated or inoculated with Bartha-K61. Mice inoculated with rPRV-HA developed hemagglutination inhibition antibodies 3 weeks post-inoculation. Twenty-eight days post-inoculation, all mice were challenged i.n. with 105.0 TCID50 of A/Swine/Heilongjiang/74/2000 (H3N2). No challenge virus was isolated from vaccinated mice, and mild pathological lesions were observed only in lungs following challenge. The results demonstrate that the recombinant rPRV-HA expressing the HA gene from H3N2 SIV can protect mice from heterologous virulent challenge, and may represent a candidate vaccine against SIV.
Keywords :
Pseudorabies virus , Recombinant virus , Swine influenza virus , H3N2 Subtype